Introduction {#s1}
============

MicroRNAs (miRNAs) are a class of small, non-coding RNAs that regulate post-transcriptional gene repression in a variety of developmental and pathological processes ([@bib2]; [@bib60]; [@bib3]; [@bib24]). Due to their small size and the imperfect nature of target recognition, miRNAs have the capacity to regulate many target mRNAs through translational repression and mRNA degradation, thereby acting as global regulators of gene expression ([@bib28]; [@bib12]). Unlike mammalian protein-coding genes that follow the one-transcript, one-protein paradigm, many miRNA genes are expressed as polycistronic primary transcripts, generating multiple mature miRNAs under the same transcriptional regulation ([@bib36]). miRNA polycistrons further expand the gene regulatory capacity, since different miRNA components can confer specific yet overlapping biological effects, and their functional interactions can yield unusual complexity.

Polycistronic miRNAs often exhibit pleiotropic biological functions with unique gene regulatory mechanisms ([@bib36]). One of the best example is *mir-17-92*, a potent oncomir (i.e., miRNA oncogene), whose genomic amplification and aberrant overexpression have been observed in many human tumors including Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), and lung cancer ([@bib31]; [@bib37]). *mir-17-92* regulates multiple cellular processes during tumor development, including proliferation, survival, angiogenesis, differentiation, and metastasis ([@bib18]; [@bib53]; [@bib6]; [@bib43]). As a polycistronic oncomir, *mir-17-92* produces a single precursor that yields six individual mature miRNAs ([Figure 1A](#fig1){ref-type="fig"}, [Figure1---figure supplement 1A](#fig1s1){ref-type="fig"}) ([@bib50]). Based on the seed sequence homology, the six *mir-17-92* components are categorized into four miRNA families ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}): *miR-17 (miR-17* and *20*)*, miR-18, miR-19 (miR-19a* and *19b*)*,* and *miR-92a* (we will designate *miR-92a* as *miR-92* in the remainder of our paper). Interestingly, *miR-92* has a more ancient evolutionary history compared to the other *mir-17-92* components ([@bib50]). *miR-92* is evolutionarily conserved in vertebrates, chordates, and invertebrates, while the remaining *mir-17-92* components are only found in vertebrates ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). Conceivably, the distinct mature miRNA sequence of each *mir-17-92* component determines the specificity of the target regulation. However, the functional significance of the *mir-17-92* polycistronic gene structure remains largely unknown.10.7554/eLife.00822.003Figure 1.*miR-92* negatively regulates the *mir-17-92* oncogenic activity in the *Eμ-myc B-lymphoma* model.(**A**) The gene structure of the *mir-17-92* polycistron and its mutated derivatives. Light colored boxes, pre-miRNAs; dark colored boxes, mature miRNAs. Homologous miRNA components are indicated by the same color. (**B**) Schematic representation of the adoptive transfer protocol using *Eμ-myc* hematopoietic stem and progenitor cells (HSPCs). *Eμ-myc/+* HSPCs were extracted from E13.5--E15.5 mouse embryos, infected with MSCV retroviral vectors overexpressing *mir-17-92* and its derivatives, and finally transplanted into lethally irradiated recipient mice. Lymphoma onset of the adoptive transferred mice was monitored to evaluate the oncogenic collaboration between c-Myc and a specific miRNA. (**C**) *miR-92* deficiency specifically accelerates the oncogenic activity of *mir-17-92* in the *Eμ-myc* model. Using the *Eμ-myc* adoptive transfer model, we compared the oncogenic effects between *mir-17-92* and *mir-17-92Δ92* and observed a significant acceleration of tumor onset in *Eμ-myc/mir-17-92Δ92* mice (p*\<0.0001*, left). When the oncogenic effects of *mir-17-92, mir-17-92Δ92* and *mir-17-92Mut92* were compared in the same adoptive transfer model, *mir-17-92Δ92* and *mir-17-92Mut92* similarly accelerated *Eμ-myc*-induced lymphomagenesis compared to *mir-17-92* (p*\<0.0001* for both comparisons, middle). Deficiency of *miR-20* failed to affect the oncogenic cooperation between *mir-17-92* and *Eμ-myc*, having minimal effects on tumor onset (right). (**D**) The mutation of *miR-92* has minimal effects on the levels of the remaining *mir-17-92* components. *Eμ-myc* B-lymphoma cells were infected with MSCV retrovirus overexpressing *mir-17-92*, *mir-17-92*Δ92 and *mir-17-92Mut92* at an MOI (multiplicity of infection) of 1. Expression levels of *miR-17, 18a, 19a, 20a, 19b* and *92* were subsequently determined using Taqman miRNA assays. Error bars indicate standard deviation (*n* = 3). \*\*p*\<*0.01, \*\*\*p*\<*0.001, \*\*\*\*p*\<*0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.003](10.7554/eLife.00822.003)10.7554/eLife.00822.004Figure 1---figure supplement 1.Gene structure and evolutionary conservation of *mir-17-92*.(**A**) A diagram represents the gene structure of *mir-17-92* and its two mammalian homologs. The six *mir-17-92* components are classified into four distinct miRNA families based on the seed sequence conservation. (**B** and **C**) *miR-92* has a more ancient evolutionary history compared to the rest of *mir-17-92* components. *miR-92* is evolutionarily conserved in Deuterostome, Ecdysozoa and Lophotrochozoa, yet the remaining *mir-17-92* components only have vertebrate homologs. (**D**) The mutation of *miR-92* or *miR-20* in the *mir-17-92* retroviral construct has minimal effects on the expression levels of the remaining *mir-17-92* components. 3T3 cells were infected with MSCV retrovirus at an MOI (multiplicity of infection) of 1 to overexpress *mir-17-92*, *mir-17-92*Δ92 and *mir-17-92Mut92* (left), or overexpress *mir-17-92Mut20* (right). Expression levels of *miR-17, 18a, 19a, 20a, 19b* and *92* were each determined using Taqman miRNA assays. Error bars indicate standard deviation (*n* = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.00822.004](10.7554/eLife.00822.004)

The structural analogy to prokaryotic operons has led to the speculation that the co-transcribed *mir-17-92* components can collectively contribute to oncogenesis. However, our studies reveal an unexpected functional interaction among *mir-17-92* components. In the *Eμ-myc* mouse B-cell lymphoma model, while the intact *mir-17-92* acts as an oncogene, its *miR-92* component negatively regulates the oncogenic cooperation with c-Myc. This effect, at least in part, results from the ability of *miR-92* to yield aberrant c-Myc dosage, which promotes a strong coupling between oncogene stress and p53-dependent apoptosis. Surprisingly, *miR-92* functionally antagonizes *miR-19*, a key oncogenic *mir-17-92* component, in the context of c-Myc-induced oncogenesis. During B-cell transformation, this *miR-19:miR-92* antagonism is disrupted to favor a greater increase of *miR-19* than *miR-92*. Thus, the polycistronic *mir-17-92* employs an antagonistic interaction among its encoded miRNA components to confer an intricate crosstalk between the oncogene and tumor suppressor networks.

Results {#s2}
=======

Since *mir-17-92* is overexpressed in human Burkitt's lymphomas ([@bib49]), we set out to functionally dissect *mir-17-92* components in the *Eμ-myc* model of Burkitt's lymphoma ([Figure 1B](#fig1){ref-type="fig"}). The *Eμ-myc* mice carry a *c-myc* transgene downstream of the immunoglobulin (*Ig*) heavy chain enhancer *Eμ* ([@bib26]; [@bib1])*,* which functionally resembles the *Ig-MYC* translocations that occur frequently in Burkitt's lymphomas ([@bib49]). The resulting B-cell specific, aberrant c-Myc activation promotes excessive proliferation, yet also evokes potent, p53-dependent apoptosis ([@bib47]; [@bib20]). Thus, c-Myc-induced apoptosis enables a self-defense mechanism against malignant transformation, producing B-lymphomas with a late onset ([@bib30]). In our adoptive transfer model ([@bib45]), *Eμ-myc/+* hematopoietic stem and progenitor cells (HSPCs) were transplanted into lethally irradiated recipient mice, generating chimeric mice that faithfully recapitulated the late tumor onset of the *Eμ-myc* transgenic mice ([Figure 1B](#fig1){ref-type="fig"}).

When *Eμ-myc/+* HSPCs were infected with MSCV (murine stem cell virus) retrovirus to overexpress the intact *mir-17-92* oncomir, we observed a considerable acceleration in tumor onset compared to the *Eμ-myc*/MSCV control mice (p\<0.01, [Figure 1C](#fig1){ref-type="fig"}). Unexpectedly, the oncogenic cooperation between c-Myc and *mir-17-92* was significantly stronger when *miR-92* was deleted within this oncomir ([Figure 1C](#fig1){ref-type="fig"}). The average survival of *Eμ-myc*/*17-92Δ92* mice was 66 days, significantly shorter than that of *Eμ-myc*/*17-92* mice (112 days, p\<0.0001). *mir-17-92Δ*92 carried a deletion of *miR-92* pre-miRNA and its flanking sequences, which might alter the expression of the remaining *mir-17-92* components ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). We then engineered a 12-nucleotide *miR-92* seed mutation within *mir-17-92* to abolish the functional *miR-92* with minimal disruption to the overall gene structure. The resulting *mir-17-92Mut92* phenocopied *mir-17-92Δ*92 in vivo ([Figure 1C](#fig1){ref-type="fig"}), significantly enhancing the oncogenic cooperation with c-Myc without altering the level of any remaining *mir-17-92* components ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). This unexpected effect was specifically attributable to *miR-92*. Mutations of *miR-20* or *miR-17* failed to affect oncogenesis in the *Eμ-myc* model ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} and data not shown), and mutations of both *miR-19* miRNAs nearly abolished this oncogenic cooperation ([@bib45]). This finding suggests that, although *mir-17-92* acted as a potent oncogene as a whole, its *miR-92* component confers an internal negative regulation on its oncogenic cooperation with c-Myc. This effect of *miR-92* clearly contrasts with that of *miR-19*, a key oncogenic *mir-17-92* component that promotes c-Myc-induced lymphomagenesis by repressing apoptosis ([@bib41]; [@bib45]; [@bib34]).

In the *Eμ-myc* model, a strong oncogenic lesion often leads to the B-cell transformation at an earlier developmental stage ([@bib20]). The greater oncogenic activity of *mir-17-92Mut92* in comparison with *mir-17-92* was consistent with *mir-17-92Mut92* preferentially transforming IgM negative progenitor B-cells, and *mir-17-92* frequently transforming IgM positive B-cells ([Figure 2A](#fig2){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). In comparison to *Eμ-myc*/*17-92* mice, both *Eμ-myc*/*17-92Δ92* and *Eμ-myc*/*17-92Mut92* mice developed more aggressive B-lymphomas, characterized by massive lymph node enlargement, splenic hyperplasia, leukemia, and widespread dissemination into visceral organs outside of the lymphoid compartment ([Figure 2B](#fig2){ref-type="fig"}, data not shown).10.7554/eLife.00822.005Figure 2.The *miR-92* deficient *mir-17-92* cooperates with c-Myc to promote highly aggressive B-lymphomas.(**A**) The percentage of IgM positive and IgM negative B-lymphomas was calculated for each genotype (*Eμ-myc/MSCV,* n = 10*; Eμ-myc/17-92,* n = 9; *Eμ-myc/17-92Δ92,* n = 10; *Eμ-myc/17-92Mut92,* n = 10). (**B**) The *Eμ-myc/17-92Mut92 and Eμ-myc/17-92Δ92* mice developed high grade B-lymphomas that were frequently disseminated into the liver. When compared to *Eμ-myc/MSCV* and *Eμ-myc/17-92* mice, *Eμ-myc/17-92Mut92 and Eμ-myc/17-92Δ92* lymphomas gave rise to more liver dissemination, as indicated by H&E and B220 staining. (**C**) *Eμ-myc/17-92Mut92* and *Eμ-myc/17-92Δ92* lymphomas exhibited a decreased apoptosis compared to *Eμ-myc/MSCV* or *Eμ-myc/17-92* lymphomas. Representative lymphomas were stained for H&E, cleaved caspase-3 and PCNA. Arrow, 'starry sky' feature of apoptotic lymphoma cells; arrowhead, apoptotic cells with positive staining for cleaved caspase-3; scale bar, 50 μm. (**D** and **E**) Apoptosis was quantitatively measured in representative lymphomas of each genotype using the 'starry sky' features (**D**) and cleaved caspase-3 staining (**E**). \*p*\<*0.05, \*\*p*\<*0.01, \*\*\*p*\<*0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.005](10.7554/eLife.00822.005)10.7554/eLife.00822.006Table 1.Flow cytometric immunophenotyping of *Eμ-myc* lymphomas with enforced expression of different *mir-17-92* derivatives**DOI:** [http://dx.doi.org/10.7554/eLife.00822.006](10.7554/eLife.00822.006)GenotypenPercentage (%)Immunotype*Eμ-myc/MSCV*440B220+, IgM−, CD19+, CD4−, CD8−660B220+, IgM+, CD19+, CD4−, CD8− [\*](#tblfn1){ref-type="table-fn"}*Eμ-myc/17--92*440B220+, IgM−, CD19+, CD4−, CD8−550B220+, IgM+, CD19+, CD4−, CD8− [†](#tblfn2){ref-type="table-fn"}110B220−, IgM−, CD19−, CD4+, CD8+*Eμ-myc/17--92Mut92*770B220+, IgM−, CD19+, CD4−, CD8−330B220+, IgM+, CD19+, CD4−, CD8− [‡](#tblfn3){ref-type="table-fn"}*Eμ-myc/1792Δ92*880B220+, IgM−, CD19+, CD4−, CD8−220B220+, IgM+, CD19+, CD4−, CD8− [§](#tblfn4){ref-type="table-fn"}[^3][^4][^5][^6]

During Myc-induced tumorigenesis, aberrant c-Myc dosage yields simultaneous induction of proliferation and apoptosis, imposing a unique selective pressure for pro-survival lesions ([@bib11]). Thus, we compared the extent of Myc-induced apoptosis in the *Eμ-myc*/*17-92, Eμ-myc*/*17-92Δ92, Eμ-myc*/*17-92Mut92*, and control *Eμ-myc*/*MSCV* lymphomas. The control *Eμ-myc/MSCV* lymphomas invariably exhibited a high proliferation index accompanied by extensive cell death, as evidenced by the widespread 'starry sky' pathology ([Figure 2C,D](#fig2){ref-type="fig"}) and cleaved caspase 3 staining ([Figure 2C,E](#fig2){ref-type="fig"}). The potent oncogenic activity of *mir-17-92Δ*92 and *mir-17-92Mut92* was consistent with the strong reduction of apoptosis in the lymph node tumors. In comparison, the intact *miR-92* significantly attenuated the repression of c-Myc-induced apoptosis by *mir-17-92* in vivo ([Figure 2C--E](#fig2){ref-type="fig"}).

We next investigated the effect of *miR-92* alone in regulating c-Myc-induced apoptosis. In the *Eμ-myc* model, *miR-92* overexpression significantly enhanced c-Myc-induced apoptosis in vivo ([Figure 3A,B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), consistent with a rapid depletion of *miR-92*-infected cells in premalignant *Eμ-myc* B-cells ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Similar *miR-92* effects on c-Myc-induced apoptosis were observed in vitro. The *R26*^*MER/MER*^ mouse embryonic fibroblasts (MEFs) carry a switchable variant of Myc, MycER^T2^, downstream of the constitutive *Rosa26* promoter, which allows acute activation of the *MycER* transgene by 4-OHT (4-Hydroxytamoxifen) induced nuclear translocation ([@bib42]). The *R26*^*MER/MER*^ MEFs recapitulate c-Myc-induced apoptosis in vitro, as activated MycER^T2^ induces p53-dependent apoptosis in response to serum starvation ([@bib42]). Enforced *miR-92* expression in *R26*^*MER/MER*^ MEFs invariably enhanced Myc-induced apoptosis ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}).10.7554/eLife.00822.007Figure 3.*miR-92* enhances both c-Myc-induced apoptosis and c-Myc-induced proliferation.(**A**) The schematic representation of the adoptive transfer model to evaluate the *miR-92* effects on the *Eμ-myc* premalignant B-cells in vivo. (**B**) *miR-92* overexpression enhances the apoptotic response in the premalignant *Eμ-myc* B-cells in vivo. Using the *Eμ-myc* adoptive transfer model, we generated well-controlled *Eμ-myc/MSCV* and *Eμ-myc/92* mice reconstituted from donor matched *Eμ-myc* HSPCs. Premalignant *Eμ-myc* splenic B-cells were isolated from the *Eμ-myc/MSCV* and *Eμ-myc/92* mice 6 weeks after reconstitution. The in vivo apoptosis was measured by the level of caspase activation using Red-VAD-FMK, a fluorescently labeled caspase inhibitor that specifically bound to cleaved caspases. The percentage of *Eμ-myc* B-cells positive for cleaved caspases was shown for four independent experiments. (**C**) Enforced *miR-92* expression in *R26*^*MER/MER*^ MEFs significantly enhanced c-Myc-induced apoptosis. *miR-92* overexpressing and the control *R26*^*MER/MER*^ MEFs were serum starved, and the MycER^T2^ transgene was activated by 4-OHT treatment. The level of apoptosis of each MEF was measured using Annexin V staining before (left) and after (middle) 4-OHT treatment and serum starvation. Quantification of c-Myc-induced apoptosis was performed in three independent MEF lines that overexpressed MSCV or *miR-92* (right panel, error bars represent SEM). (**D**) Enforced *miR-92* expression in *R26*^*MER/MER*^ MEFs significantly enhanced c-Myc-induced proliferation. Proliferative effects of *miR-92* was measured by BrdU incorporation in MycER^T2^ activated *R26*^*MER/MER*^ MEFs. *miR-92* cooperated with c-Myc to promote BrdU incorporation in both 10% (left) and 0.2% (middle) serum culture conditions. Quantification of BrdU incorporation was performed in two independent experiments (right). (**E**) *miR-92* is a potent *mir-17-92* component to promote primary B-cell proliferation. The proliferative effects of all *mir-17-92* miRNAs were measured individually in primary B-cells using BrdU incorporation. (**F**) The quantification of BrdU incorporation in experiments described in (**E**) was performed in four independent experiments. Error bars represent standard deviation, \*p*\<*0.05, \*\*p*\<*0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.007](10.7554/eLife.00822.007)10.7554/eLife.00822.008Figure 3---figure supplement 1.*miR-92* enhances c-Myc-induced apoptosis both in vitro and in vivo.(**A**) *miR-92* enhances the apoptotic response in the premalignant *Eμ-myc* B-cells in vivo. Using the *Eμ-myc* adoptive transfer model, we generated well-controlled *Eμ-myc/MSCV* and *Eμ-myc/92* mice that were reconstituted from the same *Eμ-myc* HSPCs. The in vivo apoptosis was measured by the level of caspase activation 6 weeks after the transplantation. The percentage of *Eμ-myc* B-cells positive for cleaved caspases was shown for four independent experiments. (**B**) *miR-92* infected, premalignant *Eμ-myc* B-cells is significantly depleted in the *Eμ-myc* adoptive transfer model. We generated well-controlled *Eμ-myc*/MSCV and *Eμ-myc*/92 mice reconstituted from the same *Eμ-myc* HSPCs. We measured the percentage of retrovirally infected cells (GFP+) before reconstitution (left), and demonstrated similar infection efficiency in *Eμ-myc*/MSCV and *Eμ-myc*/92 mice. At day 33 post adoptive transfer, we isolated white blood cells from the peripheral blood of these mice, and measured the percentage of retrovirally infected, *Eμ-myc* B-cells (B-220-positive; GFP-positive cells) using FACS. Error bars indicate standard deviation, n = 4, \*\*p\<0.01. (**C**) Enforced *miR-92* expression in *R26*^*MER/MER*^ MEFs significantly enhanced c-Myc-induced apoptosis. The *miR-92* effect was most evident when the infected *R26*^*MER/MER*^ MEFs were serum starved and treated with 4-OHT. (**D**) *miR-92* is required for the potent proliferative effect of *mir-17-92* in primary B-cells. *miR-92* deficient *mir-17-92* miRNA polycistrons exhibited a reduced BrdU incorporation in primary B-cell culture in vitro.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.008](10.7554/eLife.00822.008)

In addition to promoting c-Myc-induced apoptosis, *miR-92* unexpectedly enhanced c-Myc-induced cell proliferation. A significant increase of BrdU incorporation was observed in *R26*^*MER/MER*^ MEFs overexpressing *miR-92*, both under normal culture conditions and, more evidently, under serum starvation ([Figure 3D](#fig3){ref-type="fig"}). The same proliferative effect of *miR-92* was also observed in primary B-cells. Comparison of the proliferative effect of each *mir-17-92* component in bone marrow derived primary B-cells revealed that the *miR-92* component yielded one of the strongest effects ([Figure 3E,F](#fig3){ref-type="fig"}). In addition, *miR-92* deficiency significantly compromised the ability of *mir-17-92* to promote cell cycle progression in B-cells ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Interestingly, strong proliferative effects have been reported for nearly all *mir-17-92* components, yet the exact cell type and biological context can select specific components as the predominant drivers for cell proliferation. Taken together, our data suggest that *miR-92* is a unique *mir-17-92* component that functionally couples c-Myc-induced cell proliferation and c-Myc-induced apoptosis in the B-cell compartment.

To investigate the molecular mechanism underlying *miR-92* functions, we performed microarray analyses comparing gene expression profiles of *R26*^*MER/MER*^ MEFs overexpressing *miR-92* or the control MSCV vector*.* These MEFs were serum starved and 4-OHT treated to trigger strong Myc-induced apoptosis. *miR-92*-upregulated genes were significantly enriched for the cell cycle pathway, including *ccnd1*, *ccnb1*, *ccnb2*, *cdc25b, cdc25c,* and *cdk4* ([Figure 4A,B](#fig4){ref-type="fig"}), consistent with the ability of *miR-92* to promote Myc-induced cell proliferation. Genes upregulated by *miR-92* were also enriched for the *p53* pathway, including the classic *p53* target *mdm2*, as well as the pro-apoptotic p53 targets---*noxa*, *bax*, *puma*, *perp*, and *bid* ([Figure 4A,B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Since aberrant c-Myc activation triggered a p53-dependent apoptotic response ([@bib30]), our observation is consistent with *miR-92* further enhancing p53 activation downstream of c-Myc. Interestingly, *p21*, a canonical p53 target, was not induced by *miR-92* in the MycER^T2^ activated *R26*^*MER/MER*^ MEFs ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). It is likely that the transcriptional repression of *p21* by c-Myc renders *p21* irresponsive to p53 activation under this biological context ([@bib19]). Using real-time PCR, we validated the ability of *miR-92* to induce cell cycle genes and activate p53 targets in both *R26*^*MER/MER*^ MEFs, as well as primary B-cells ([Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). Hence, the molecular signature imposed by *miR-92* overexpression is consistent with its functional readout.10.7554/eLife.00822.009Figure 4.*miR-92* induces apoptosis through the activation of the p53 pathway.(**A**) The genes upregulated by *miR-92* were enriched for the cell cycle pathway and the *p53* pathway. Microarray analyses compared gene expression profiles of serum starved and 4-OHT treated *R26*^*MER/MER*^ MEFs overexpressing either *miR-92* or a control MSCV vector (n = 3). The differentially expressed genes were defined as those with at least 1.5-fold expression level change using SAM (Significance analysis of microarrays, false discovery rate \<1%). Pathway analyses were performed on upregulated and downregulated genes using the KEGG database. (**B**) The heatmaps of the *miR-92* upregulated genes enriched for the cell cycle and p53 pathways. (**C**) Components of the cell cycle and p53 pathways were upregulated upon *miR-92* overexpression in both MEFs (left) and primary B-cells (right). The quantitation of gene expression was performed using real time PCR. (**D**) *miR-92* overexpression induces the accumulation of Arf and p53 proteins in MEFs and primary B-cells from bone marrow. Western analyses were performed on the *R26*^*MER/MER*^ MEFs (left) and primary B-cells (right) that overexpressed *miR-92* or a control MSCV vector in two independent experiments. The infected *R26*^*MER/MER*^ MEFs were assayed at 6 hr after serum starvation and 4-OHT treatment; the infected primary B-cells were collected 72 hr post infection. (**E**) The apoptotic effect of *miR-92* requires an intact p53 pathway. We infected *R26*^*MER/MER*^ MEFs with two MSCV retrovirus, MSCV-p53shRNA and MSCV-92, to obtain doubly infected cells. Knocking down *p53* in *R26*^*MER/MER*^ MEFs abolished the ability of *miR-92* to enhance c-Myc-induced apoptosis, as measured by Annexin V staining (two left panels). The percentage of apoptotic MEFs of each experimental condition was quantitatively measured (right). (**F**) The induction of the p53 pathway components by *miR-92* is dependent on an intact p53. Knocking down *p53* in *R26*^*MER/MER*^ MEFs abolished the ability of *miR-92* to induce pro-apoptotic p53 targets and other canonical p53 targets, including *noxa*, *perp* and *mdm2*. Error bars represent standard deviation, \*p*\<*0.05, \*\*p*\<*0.01, \*\*\*p*\<*0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.009](10.7554/eLife.00822.009)10.7554/eLife.00822.010Figure 4---figure supplement 1.*miR-92* overexpression triggers the activation of the p53 pathway.(**A**) *miR-92* overexpression in *R26*^*MER/MER*^ MEFs induced several p53 target genes in addition to those described in [Figure 3C](#fig3){ref-type="fig"}, including *mdm2*, *Gtse1* and *Bid,* but not *p21*. (**B**) Induction of p53 targets by *miR-92* in *R26*^*MER/MER*^ MEFs with and without MycER^T2^ activation. (**C**) *miR-92* overexpression alone enhanced Arf and p53 protein level in *R26*^*MER/MER*^ MEFs with and without 4-OHT treatment. (**D**) *miR-92* overexpression did not affect p53 mRNA levels in either primary B-cells or in *R26*^*MER/MER*^ MEFs. Error bars indicate standard deviation, n = 3, \*p*\<*0.05; \*\*p*\<*0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.010](10.7554/eLife.00822.010)

The activation of the p53 pathway by c-Myc is essential for the induction of the apoptotic response in the *Eμ-myc* model ([@bib47]). A major mechanism that governs Myc-induced p53 activation is the transcriptional induction of the gene encoding *Arf*, which inhibits Mdm2-mediated p53 ubiquitination and degradation ([@bib30]; [@bib5]). The ability of *miR-92* to enhance c-Myc-induced apoptosis and to increase the expression of p53 targets raised the possibility that *miR-92* overexpression activates p53 possibly through elevated Arf. In both *R26*^*MER/MER*^ MEFs and wild-type primary B-cells, *miR-92* overexpression alone caused significant accumulation of Arf mRNA and protein ([Figure 4C,D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), consistent with the rapid stabilization of the p53 protein ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}) without alteration of *p53* mRNA ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Notably, the ability of *miR-92* to induce p53 activation occurred not only in 4-OHT treated *R26*^*MER/MER*^ MEFs with MycER^T2^ activation, but also in untreated *R26*^*MER/MER*^ MEFs with normal c-Myc level. This was clearly demonstrated by the elevation of p53 protein level, as well as the increased p53 target expression ([Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}).

The induction of p53 by *miR-92* prompted us to investigate the functional importance of p53 in *miR-92*-induced apoptotic response. Knockdown of *p53* in *R26*^*MER/MER*^ MEFs not only led to a suppression of c-Myc-induced apoptosis, but also completely abolished the effect of *miR-92* to enhance c-Myc-induced apoptosis ([Figure 4E](#fig4){ref-type="fig"}). These findings suggested that an intact p53 pathway is required for the apoptotic effect of *miR-92*. Consistently, the *miR-92* induction of the pro-apoptotic genes, including *noxa*, *perp,* and *mdm2*, also was mediated by the intact p53 ([Figure 4F](#fig4){ref-type="fig"}). Thus, aberrant c-Myc activation triggers an apoptotic response through p53 activation; and co-expression of *miR-92* with c-Myc leads to an even stronger p53 activation, and subsequently apoptotic response.

Our findings suggest parallels between *c-myc* and *miR-92*: both are potent oncogenes that promote excessive cell proliferation coupled with p53-dependent apoptosis, and both are capable to induce expression of cell cycle genes (*ccnb1, ccnd1, cdk4,* and *cdc25*) ([@bib30]; [@bib5]) and p53 pathway components (*Arf, puma, noxa, perp,* and *mdm2*) ([@bib30]; [@bib5]). The functional analogy between c-Myc and *miR-92*, as well as the molecular overlap between their downstream pathways, led us to investigate the effect of *miR-92* on c-Myc. Intriguingly, *miR-92* expression significantly enhanced c-Myc protein level both in MEFs and in primary B-cells ([Figure 5A](#fig5){ref-type="fig"}), without affecting the *c-myc* mRNA level ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, data not shown). Consistent with the stabilization of endogenous c-Myc, *miR-92* overexpression in *R26*^*MER/MER*^ MEFs stabilized the MycER^T2^ protein ([Figure 5B](#fig5){ref-type="fig"}). The dosage of c-Myc protein is crucial for its biological readout ([@bib42]). While c-Myc dosage determines the extent of cell cycle gene induction and cell proliferation, it also regulates the degree of p53 activation and subsequent apoptosis ([@bib42]) ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Thus, the ability of *miR-92* to induce aberrant c-Myc accumulation likely constitutes the molecular basis for its ability to promote both cell proliferation and p53-dependent apoptosis.10.7554/eLife.00822.011Figure 5.*miR-92* promotes the accumulation of c-Myc protein through repressing Fbw7.(**A**) *miR-92* enhances the accumulation of c-Myc protein in synchronized *R26*^*MER/MER*^ MEFs (upper), as well as primary B-cells (lower). The *miR-92* overexpression and the control *R26*^*MER/MER*^ MEFs were synchronized by serum starvation and were collected 12 hr after being released into serum culture conditions to determine the c-Myc protein level. This synchronization approach in *R26*^*MER/MER*^ MEFs has provided us with the most consistent measurement for c-Myc protein level, because it is regulated in a cell-cycle-dependent manner. (**B**) *miR-92* overexpression decreases the turnover of c-Myc protein. Serum-synchronized *R26*^*MER/MER*^ MEFs that overexpress either *miR-92* or the control MSCV vector were released into the serum for 6 hr, treated with cycloheximide, collected at the indicated time points, then analyzed by western blot to determine the levels of MycER and the endogenous c-Myc protein. (**C**) Schematic representation of the two *miR-92* binding sites in the murine *fbw7* 3′UTR. Additionally, a luciferase reporter and a *FLAG* tagged *fbw7* ORF were each placed upstream of a wild-type *fbw7* 3′UTR, or a mutated *fbw7* 3′UTR that abolished the predicted *miR-92* binding. (**D**) The expression of *Luc-fbw7-3′UTR* was specifically repressed by *miR-92* in *Dicer*^*−/−*^ HCT116, while mutations of the two putative *miR-92* binding sites within the *fbw7-3′UTR (Luc-fbw7-*3′UTRMut) abolished this repression. (**E**) The endogenous *fbw7* gene was downregulated by *miR-92* post-transcriptionally. Both the endogenous *fbw7* mRNA (left) and the endogenous Fbw7 protein (right) were repressed upon *miR-92* overexpression in *R26*^*MER/MER*^ MEFs. Due to the lack of a proper antibody to detect endogenous Fbw7 in regular western analysis, we demonstrated the downregulation of endogenous Fbw7 by *miR-92* using immunoprecipitation followed by immunoblotting with a polyclonal anti-Fbw7 antibody. (**F**) *miR-92* enhances the accumulation of Cyclin E protein. Overexpression of *miR-92* increased the accumulation of Cyclin E protein, which was further confirmed by the increased Cyclin E-dependent kinase activity. (**G**) The knockdown of *fbw7* resembles the effect of *miR-92* to enhance c-Myc-induced apoptosis. Knocking down *fbw7* in *R26*^*MER/MER*^ MEFs enhanced c-Myc-induced apoptosis, partially recapitulating the phenotype caused by *miR-92* overexpression. Apoptosis was quantitatively measured by Annexin V staining in two independent lines of *R26*^*MER/MER*^ MEFs upon serum starvation and 4-OHT treatment. (**H**) Overexpression of *fbw7* abolished the apoptotic effects of *miR-92* in *R26*^*MER/MER*^ MEFs. *R26*^*MER/MER*^ MEFs were doubly infected by pRetro-*fbw7αΔ3′UTR*-IRES-dsRed and MSCV-*miR-92*. The c-Myc-induced apoptosis was quantitatively measured by Annexin V staining in doubly infected *R26*^*MER/MER*^ MEFs upon serum starvation and 4-OHT treatment. Error bars represent standard deviation). \*p*\<*0.05; \*\*p*\<*0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.011](10.7554/eLife.00822.011)10.7554/eLife.00822.012Figure 5---figure supplement 1.*miR-92* overexpression enhances c-Myc protein level by repressing Fbw7.(**A**) *miR-92* overexpression did not affect *c-myc* mRNA levels in two independent primary B-cells. (**B**) The c-Myc dosage determines the degree of c-Myc-induced apoptosis in *R26*^*MER/MER*^ MEFs. When *R26*^*MER/MER*^ MEFs were compared with *R26*^*MER/+*^ MEFs, a twofold increase in the MycER^T2^ dosage significantly enhanced the c-Myc-induced apoptotic response upon serum starvation. This effect was observed in *R26*^*MER/MER*^ MEFs either with or without *miR-92* overexpression. (**C**) Negative regulators of c-Myc that contain a putative *miR-92* binding site(s) were screened for *miR-92-*mediated repression in *R26*^*MER/MER*^ MEFs that overexpress *miR-92* or a control MSCV vector. Only *fbw7* exhibited a *miR-92*--mediated repression. (Error bars indicate standard deviation, n = 3, \*\*p*\<*0.01). (**D**) The expression of *FLAG-fbw7-*3′UTR was significantly repressed by *miR-92* in *Dicer*^*−/−*^ HCT116 cells. (**E**) *fbw7* is downregulated in *Eμ-myc* lymphomas that overexpress *miR-92*. A panel of *Eμ-myc/MSCV* (n = 9), *Eμ-myc/17-92* (n = 7), *Eμ-myc/17-92Δ92* (n = 6) and *Eμ-myc/17-92Mut92* (n = 5) lymphomas were compared for their expression level of endogenous *fbw7*. *Eμ-myc/17--92* lymphomas exhibited a specific decrease of *fbw7* compared to the other genotypes*,* possibly due to the *miR-92* overexpression. (**F**) The c-MYC upregulation by *miR-92* requires an intact *fbw7*. The effect of *miR-92* to upregulate c-MYC protein level was observed in wild-type Hct116 cells, but largely absent in *FBW7*^−/−^ Hct116 cells. (**G**) *fbw7* knockdown by RNAi in *R26*^*MER/MER*^ MEFs recapitulated the c-Myc upregulation by *miR-92*. (**H**) *fbw7* expression level in *R26*^*MER/MER*^ MEFs infected with pRetroX-*fbw7*-IRES-DsRedExpress. Error bars indicate standard deviation, \*p*\<*0.05; \*\*p*\<*0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.012](10.7554/eLife.00822.012)

Based on our findings, we speculated that *miR-92* targets could include negative regulators of c-Myc protein accumulation. Therefore, we searched genes known to negatively regulate *c-myc* for the presence of putative *miR-92* binding sites. Using the Targetscan and RNA22 algorithms ([@bib28]; [@bib40]; [@bib3]), we identified eight candidate *miR-92* targets, each of which contained one or more predicted *miR-92* binding sites in the 3′ untranslated region (3′UTR). Real-time PCR analysis of these candidate genes confirmed *fbw7* (F-box and WD repeat domain-containing 7) as a likely target of *miR-92* ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). *fbw7*, which contains two *miR-92* target sites within its 3′UTR ([Figure 5C](#fig5){ref-type="fig"}), is the substrate recognition component of an SCF-type E3 ubiquitin ligase that mediates the degradation of several proto-oncoproteins, including Myc, Cyclin E, c-Jun, and Notch ([@bib56]; [@bib7]; [@bib55]). A luciferase reporter or a FLAG-tagged *fbw7*-encoding ORF (open reading frame), when fused to the wild-type *fbw7* 3′ UTR, were both significantly repressed in a *miR-92* dependent manner ([Figure 5D](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"})*.* Yet enforced *miR-92* expression failed to repress the luciferase reporter that contained an *fbw7* 3′UTR with two mutated *miR-92* binding sites ([Figure 5D](#fig5){ref-type="fig"}), suggesting that *miR-92* binding to *fbw7* 3′UTR is required for this repression. Furthermore, *miR-92* effectively repressed endogenous Fbw7 protein level, as demonstrated by the decreased *fbw7* mRNA level and Fbw7 immunoprecipitation ([Figure 5E](#fig5){ref-type="fig"}). Consistent with *fbw7* as an important target for *miR-92*, enforced *miR-92* expression upregulated multiple *Fbw7* substrates at their protein levels, including c-Myc and cyclinE ([Figure 5F](#fig5){ref-type="fig"}). Observations from our in vivo experiments also supported this post-transcriptional regulation of Fbw7 by *miR-92*, as we observed an inverse correlation between the level of *miR-92* and *fbw7* when comparing *Eμ-myc/17-92Δ92 and Eμ-myc/17-92* lymphoma cells ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}).

*fbw7* has previously been postulated as a potential *miR-92* target based on the presence of *miR-92* target sites ([@bib35]), yet it remains unclear how *fbw7* mediated the pro-apoptotic effects of *miR-92*, given its well-characterized functions as a tumor suppressor. Recent findings indicate that the acute inactivation of tumor suppressor Fbw7 imposes a strong oncogenic stress to induce p53-dependent apoptosis, conferring a selective advantage to cells with deficient p53 function ([@bib39]; [@bib46]; [@bib33]; [@bib15]). This p53-dependent apoptosis is, at least in part, due to an aberrant increase of c-Myc dosage ([@bib46]; [@bib33]). These findings suggested that a major mechanism through which *miR-92* enhanced the c-Myc protein level, and subsequently, c-Myc-induced apoptosis, could be through its direct repression of Fbw7. In support of this hypothesis, *miR-92* overexpression significantly increased the c-Myc protein level in wild-type Hct116 cells, but not in *FBW7*^−/−^ Hct116 cells ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}), suggesting *FBW7* was essential for *miR-92* to induce c-MYC increase. Functionally, acute *fbw7* knockdown in *R26*^*MER/MER*^ MEFs partially phenocopied the effect of *miR-92* to enhance c-Myc-induced apoptosis ([Figure 5G](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1G](#fig5s1){ref-type="fig"}); while overexpression of an *fbw7α* open reading frame (ORF), albeit above its physiological level, completely abolished this apoptotic effect of *miR-92* ([Figure 5H](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1H](#fig5s1){ref-type="fig"}). Nevertheless, it is still likely that additional mechanisms downstream of *miR-92* also promote its apoptotic effects, because *fbw7* knockdown largely recapitulated the extent of c-Myc upregulation by *miR-92* ([Figure 5---figure supplement 1G](#fig5s1){ref-type="fig"}), yet only partially phenocopied its pro-apoptotic effects ([Figure 5G](#fig5){ref-type="fig"}). In addition, overexpression of *fbw7* above its physiological level might amplify the extent of functional interactions between *fbw7* and *miR-92* in regulating apoptosis. Despite these caveats, our results strongly argue that the *miR-92*-Fbw7 axis constitutes a major mechanism underlying the pro-apoptotic effects of *miR-92*.

Downregulation of Fbw7 by *miR-92* significantly enhanced the protein level of c-Myc in *R26*^*MER/MER*^ MEFs and in primary B-cells ([Figure 5A](#fig5){ref-type="fig"}). It is conceivable that the ability of *miR-92* to repress Fbw7 in vivo could similarly enhance the c-Myc accumulation in the *Eμ-myc/92* premalignant B-cells, promoting rapid cell proliferation and a p53-dependent apoptotic response. Unfortunately, due to technical limitations, we were not able to demonstrate an increased c-Myc protein level as a result of *miR-92* overexpression in the *Eμ-myc* premalignant B-cells. There was a significant depletion of the *Eμ-myc/92* premalignant B-cells due to excessive apoptosis ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), making it difficult to collect enough cells to analyze the c-Myc protein level by western analyses. Similarly, we could not obtain enough cells to compare the protein level of c-Myc in the premalignant B-cells from the *Eμ-myc/17-92*, *Eμ-myc/17-92Δ92,* and *Eu-myc/MSCV* animals. Nevertheless, our functional studies in cell culture, combined with the inverse expression correlation between *fbw7* and *miR-92* in vivo, strongly argue the importance of the *miR-92*-Fbw7-Myc axis to promote the pro-apoptotic effects of *miR-92*.

In the context of the c-Myc cooperation, *mir-17-92* encodes miRNA components with opposing biological functions. While *miR-19* miRNAs repress c-Myc-induced apoptosis to promote *Eμ-myc* lymphomagenesis ([@bib41]; [@bib45]), *miR-92* enhances c-Myc-induced apoptosis to attenuate the tumorigenic effects. Consistent with the opposing effects of *miR-19* and *miR-92*, co-expression of these two miRNAs as a dicistron attenuated the apoptotic effect of *miR-92* in premalignant *Eμ-myc* B-*cells* in vivo ([Figure 6A,B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). A similar antagonistic interaction was also observed in *R26*^*MER/MER*^ MEFs; and introducing a *miR-19b* mutation within *mir-19b-92* dicistron abolished this interaction ([Figure 6C](#fig6){ref-type="fig"}). Since *miR-19* represses *pten* to promote the PI3K/AKT pathway, the activation of AKT signaling would lead to increased phosphorylation of Mdm2, thus destabilizing p53 to dampen the apoptotic response induced by *miR-92* ([@bib13]; [@bib44]). Consistent with this hypothesis, we observed a decreased p53 induction and an unaltered c-Myc level when *miR-92* was co-expressed with *miR-19* ([Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}).10.7554/eLife.00822.013Figure 6.The antagonistic interaction between *miR-19* and *miR-9*2 regulates the balance between proliferation and apoptosis.(**A**) The schematic representation of the *Eμ-myc* adoptive transfer model to evaluate the functional interaction between *miR-92* and *miR-19* in vivo. Light colored boxes, pre-miRNAs; dark colored boxes, mature miRNAs. (**B**) *miR-19* antagonizes the apoptotic effects of *miR-92* in vivo. *miR-92* overexpression in the *Eμ-myc* adoptive transfer model enhanced apoptosis in premalignant *Eμ-myc* splenic B-cells, while the *mir-19b-92* dicistron expression abolished this apoptotic effect (left three panels). A quantitative analysis of apoptosis by FACS was shown for three independent, well-controlled experiments (right). (**C**) *miR-19b* dampens the *miR-92*-induced apoptosis in MycER^T2^ activated *R26*^*MER/MER*^ MEFs. *R26*^*MER/MER*^ MEFs were infected by *miR-92*, *mir-19b-92*, *mir-19b-92Mut19b* and the MSCV control vector, and were subsequently serum starved and treated with 4-OHT to activate MycER^T2^. Apoptosis in these samples was measured quantitatively using Annexin V staining (left four panels). The extent of apoptosis induced by MSCV, *miR-92*, *mir-19b-92*, *mir-19b-92Mut19b* was normalized to that of MSCV infected *R26*^*MER/MER*^ MEFs and then averaged from four independent experiments (right). (**D**) *miR-19b* dampens the *miR-92*-induced p53 activation. *R26*^*MER/MER*^ MEFs that overexpress the indicated constructs (*miR-92*, *mir-19b-92Mut19b* and *mir-19b-*92) were collected 48 hr after infection and then analyzed by western blot to determine the level of p53 protein. (**E**) *miR-92* and *miR-19* exhibit antagonistic effects to regulate hydroxyurea (HU)-induced cell death in *Xenopus* embryos. Representative images of HU-treated *Xenopus* embryos that were co-injected with human Ago2 and the indicated miRNA mimics (left). Co-injection of *miR-92* dampened the cell survival effects of *miR-19* on HU-induced apoptosis (right, n = 3, with \>20 embryos in each group). (**F**) *miR-92* exhibits a specific antagonistic interaction with *miR-19*. Injection of *miR-19a* or *miR-19b* rescued HU-induced apoptosis in *Xenopus* embryos. Co-injection of *miR-92*, but not a mutated *miR-92*, or other *mir-17-92* components, dampened the cell survival effect of *miR-19* (n = 3, with \>20 embryos in each group). Error bars represent standard deviation, \*p*\<*0.05; \*\*p*\<*0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.013](10.7554/eLife.00822.013)10.7554/eLife.00822.014Figure 6---figure supplement 1.Functional antagonism between *miR-19:miR-92* regulates the balance between proliferation and apoptosis.(**A**) *miR-19* antagonizes the apoptotic effects of *miR-92* in vivo. *miR-92* overexpression enhanced apoptosis in premalignant *Eμ-myc* bone marrow B-cells in vivo, while co-expression of *miR-19* and *miR-92* as a dicistron (*mir-19b-92*) abolished this apoptotic effect (left three panels). A quantitative analysis of apoptosis by FACS was shown for three independent experiments (right). (**B**) *miR-19* has no effects on the level of c-Myc protein. While *miR-92* overexpression significantly enhanced the level of c-Myc in *R26*^*MER/MER*^ MEFs, co-expression of *miR-19b* and *miR-92* did not reverse the increase in c-Myc expression. In addition, *miR-19b* expression alone did not impact the dosage of c-Myc protein. (**C**) *Xenopus fbw7* contains one predicted target site for *miR-92*. This predicted *miR-92* binding site is conserved between *Xenopus* and mouse.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.014](10.7554/eLife.00822.014)

This *miR-19:miR-92* antagonism appears to be conserved evolutionarily. In *Xenopus laevis, miR-19* and *miR-92* have identical sequence to their mammalian orthologs ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Based on Targetscan and RNA22 miRNA target prediction algorisms ([@bib27], [@bib28]; [@bib40]; [@bib16]), their target specificity is also conserved for key miRNA targets, although the exact binding sites may or may not be conserved ([@bib45]) ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). In addition, the biological functions of *miR-19* and *miR-92* exhibit evolutionary conservation between *Xenopus laevis* and mammals. Individual injection of *miR-19* promoted cell survival of hydroxyurea-treated *Xenopus* embryos, while co-injection of *miR-19a* and *miR-92* significantly attenuated this pro-survival effect ([Figure 6E](#fig6){ref-type="fig"}). This functional antagonism was specific for *miR-92* and *miR-19*, since co-injection of other *mir-17-92* components or a mutated *miR-92* did not yield any functional interactions in combination with *miR-19* ([Figure 6F](#fig6){ref-type="fig"}).

Given the opposing biological effects of *miR-19* and *miR-92* during c-Myc-induced lymphoma development, differential regulation of these two miRNA families could determine the oncogenic activity of *mir-17-92*. Under normal physiological conditions, this *miR-19*:*miR-92* antagonism could attenuate the detrimental oncogenic signaling by inducing apoptosis in cells with inappropriate *mir-17-92* induction. During malignant transformation, and particularly during c-Myc-induced oncogenesis, this *miR-19*:*miR-92* antagonism could be disrupted to favor cell survival. Using real time PCR analyses, we compared the relative abundance of *miR-19*a, *miR-19*b, and *miR-92* in normal splenic B-cells, premalignant *Eμ-myc* B-cells, and *Eμ-myc* lymphomas ([Figure 7A](#fig7){ref-type="fig"}). Comparing to normal splenic B-cells, the levels of all three mature miRNA species were elevated in both premalignant and malignant *Eμ-myc* B-cells, possibly due to transcriptional activation of *mir-17-92* by c-Myc ([@bib10]). However, the *miR-19* to *miR-92* ratios significantly increased during c-Myc-induced lymphomagenesis ([Figure 7B](#fig7){ref-type="fig"}). In other words, when normalized to the respective miRNA levels in normal splenic B-cells, mature *miR-19* (including *miR-19a* and *miR-19b*) exhibited a greater increase in premalignant and malignant *Eμ-myc* B-cells than mature *miR-92* ([Figure 7A--C](#fig7){ref-type="fig"}). This differential increase was most evident in premalignant *Eμ-myc* B-cells; the fully transformed *Eμ-myc* B-lymphoma cells exhibited a lesser difference ([Figure 7A,B](#fig7){ref-type="fig"}). This observation is consistent with premalignant *Eμ-myc* B-cells having an intact p53-dependent apoptotic response, thus a stronger selective pressure for a greater *miR-19:miR-92* ratio. In comparison, most *Eμ-myc* B-lymphomas have a defective p53 response, hence a less strong selective pressure to maintain a high *miR-19:miR-92* ratio. We also validated this observation using northern analysis. Comparing normal splenic B-cells and multiple *Eμ-myc* lymphoma cells, the levels of the mature *miR-19a, miR-19b* and *miR-92* were all elevated in transformed B-cells; however, the degree of increase for *miR-19a* and *miR-19b* was significantly higher than that of *miR-92* ([Figure 7C](#fig7){ref-type="fig"}). This differential increase of *miR-19* and *miR-92* was also observed in human Burkitt's lymphoma cell lines when compared to normal B-cells isolated from the periphery blood ([Figure 7D](#fig7){ref-type="fig"}). More importantly, this phenomenon was not limited to *c-myc* driven B-lymphomas. In the LT2-MYC murine model of hepatocellular carcinoma (HCC), where tumor development was initiated by tetracycline-inducible c-Myc expression, *miR-19a* and *miR-19b* also exhibited a stronger increase than *miR-92* when comparing tumor cells and the normal counterpart ([Figure 7E](#fig7){ref-type="fig"}).10.7554/eLife.00822.015Figure 7.The *miR-19*:*miR-9*2 antagonism is disrupted during malignant transformation.(**A** and **B**) Compared to normal splenic B-cells, premalignant and malignant *Eμ-myc* B-cells favored a greater increase in mature *miR-19* (*miR-19a* and *miR-19b*) than *miR-92*. The purified normal splenic B-cells, premalignant *Eμ-myc* bone marrow B-cells and malignant *Eμ-myc* B-lymphoma cells were subjected to Taqman miRNA assays to determine the expression level of *miR-19a*, *miR-19b* and *miR-92*. Comparing premalignant/malignant *Eμ-myc* B-cells vs normal splenic B-cells, all three miRNAs exhibited an increased level, although the increase in *miR-19a* or *miR-19b* was significantly higher than that of *miR-92* (**A**). In the same experiment, the relative ratios for *miR-19a:miR-92* and *miR-19b:miR-92* were measured for all normal splenic B-cells and *Eμ-myc* B-cells (**B**). (**C**) Mature *miR-19* and *miR-92* are differentially expressed in normal splenic B-cells and *Eμ-my*c B-lymphoma cells. The normal splenic B-cells, immortalized human B-cells, premalignant *Eμ-myc/+* B-cells, and *Eμ-myc/+* B-lymphoma cells were subjected to Northern analysis. Compared to normal splenic B-cells, both malignant and premalignant *Eμ-myc/+* B-cells favored a greater increase of *miR-19* than *miR-92*. (**D**) Compared to normal B-cells isolated from peripheral blood, human Burkitt's lymphoma cell lines favor a greater increase in mature *miR-19* than *miR-92*. (**E**) Compared to normal livers (LT2), mouse hepatocellular carcinomas caused by the inducible c-Myc over-expression (LT2-*myc*) favor a greater increase in mature *miR-19* than *miR-92*. (**F**) A diagram describes our proposed model to explain the functional interactions between *miR-92* and *miR-19* in c-Myc-induced B-lymphomagenesis. Aberrant c-Myc expression couples rapid proliferation and p53-dependent apoptosis. *miR-92* overexpression further increases c-Myc dosage to strengthen this coupling, at least in part by repressing Fbw7. This *miR-92* effect ensures a potent mechanism to eliminate premalignant c-Myc overexpressing cells. Interestingly, *miR-92* and can be antagonized by the survival effects of the *miR-19* miRNAs encoded by the same *mir-17-92* miRNA polycistron. Taken together, while *miR-19* miRNAs repressed c-Myc-induced apoptosis to promote the oncogenic cooperation between *mir-17-92* and c-Myc, *miR-92* exhibits a negative regulation. Thus, the antagonistic interactions between *miR-92* and *miR-19* confer an intricate crosstalk between proliferation and apoptosis. Error bars represent standard deviation, \*p*\<*0.05; \*\*p*\<*0.01, \*\*\*p*\<*0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.00822.015](10.7554/eLife.00822.015)

These observations were consistent with a previous finding, where the inducible *c-myc* activation in a human Burkitt's lymphoma cell line induced both *miR-19a* and *miR-19b* to a greater extent than *miR-92* ([@bib10])*.* Although *miR-19* and *miR-92* are co-transcribed from the *mir-17-92* precursor, the differential increase of *miR-19* vs *miR-92* occurs in multiple c-Myc-driven tumor types. Thus, the relative abundance of *miR-19* and *miR-92* could constitute an important molecular basis to regulate the initiation and progression of c-Myc-induced tumor development.

Discussion {#s3}
==========

The unique polycistronic structure of *mir-17-92* constitutes the basis for its pleiotropic functions and the complex mode of interactions among its miRNA components. A high level of *mir-17-92* in normal or premalignant cells could lead to suboptimal consequences that are counter-balanced through an intrinsic negative regulation by *miR-92* ([Figure 7F](#fig7){ref-type="fig"}). As we demonstrated in vitro where *miR-92*, by directly downregulating Fbw7, enhances c-Myc protein level to promote apoptosis, the ability of *miR-92* to repress Fbw7 in vivo could similarly constitute a major mechanism to enhance c-Myc-induced apoptosis. This effect of *miR-92* is a double edged sword in c-Myc driven tumors, as its overexpression gives rise to a strong and obligated coupling between excessive proliferation and a potent, p53-dependent apoptosis ([Figure 7F](#fig7){ref-type="fig"}). This coupling is consistent with the previous observation that a lower level of constitutive c-Myc acts more effectively to promote tumor initiation, while a higher level of c-Myc is selected by the terminal tumors with defective apoptosis machinery ([@bib42]). Therefore, *mir-17-92* encodes an internal component to confer a negative regulatory feedback on its oncogenic activity, imposing a strong selection for anti-apoptotic lesions to shape the path of malignant transformation. More interestingly, c-Myc transcriptionally activates *mir-17-92* that encodes *miR-92* ([@bib21]), which in turn enhances c-Myc dosage, at least in part, by repression Fbw7. It is possible that aberrant c-Myc activation triggers a positive feedback loop to further increase c-Myc dosage to strengthen the apoptotic response and to eliminate cells with oncogenic potential. It is worth noting that the *miR-92* apoptotic effect described in this study depends on an intact p53 response. Consequently, in terminal *Eμ-myc* B-lymphoma cells that often carry a defective p53 response, *miR-92* failed to enhance c-Myc-induced apoptosis ([@bib41]).

The functional readout of *miR-92* heavily depends on cell types and biological contexts. It is important to recognize that *miR-92* is not a tumor suppressor miRNA. Like c-Myc, *miR-92* elicits potent oncogene stress to engage tumor suppressor response, at least in part, by activating p53. In the premalignant *Eμ-myc/92* B-cells, the effect of *miR-92* to repress Fbw7 most likely results in an increase of c-Myc level, which coupled with the intact p53 response to strongly sensitize the cells to *miR-92*-induced apoptosis. Under other contexts when proliferation becomes a rate-limiting event for oncogenesis, or when p53-dependent apoptosis is compromised, *miR-92* could render a pro-proliferative effect that is strictly oncogenic ([@bib51]). Likewise, the functional readout of other *mir-17-92* components also heavily depends on cell types and biological contexts. *miR-19* promotes c-Myc-induced B-lymphomas by repressing apoptosis ([@bib41]; [@bib45]), yet has little effects in promoting *Rb*-deficient retinoblastomas ([@bib6]); *miR-17* allows the bypass of Ras-induced senescence by promoting proliferation ([@bib22]), yet fails to affect c-Myc-induced lymphomas, possibly due to its functional redundancy with c-Myc.

Both cooperative and antagonistic interactions operate among subsets of *mir-17-92* components. The *miR-19:miR-92* antagonism constitutes a novel mechanism to confer an intricate balance between oncogene signaling and innate tumor suppressor responses ([Figure 7F](#fig7){ref-type="fig"}). This balance can be disrupted in premalignant and malignant cells that exhibit c-Myc overexpression, as an increase in the *miR-19*:*miR-92* ratio is likely to favor the suppression of c-Myc-induced apoptosis and to promote oncogenesis. Although all *mir-17-92* components are co-transcriptionally regulated, different changes of *miR-19* vs *miR-92* during oncogenesis could be a result of differential miRNA biogenesis and/or turn-over. It has been shown that specific RNA-binding proteins, such as hnRNP A1, promote the processing of a specific *mir-17-92* component, *miR-18* ([@bib17]). Future studies are likely to reveal important mechanisms underlying cell type- and context-dependent differential regulation of *mir-17-92* components, which will generate important insights on the biology of polycistronic miRNAs.

Our current study mostly focuses on the antagonistic interaction between *miR-19* and *miR-92* in c-Myc driven oncogenesis, yet it reveals a more general mechanism underlying the structural function relationship of polycistronic miRNAs. It is likely that the complex interactions among polycistronic miRNA components can coordinate and balance a multitude of cellular and molecular processes during normal development and disease. Interestingly, in the case of *mir-17-92*, *miR-92* has a different evolutionary history compared to the other *mir-17-92* components. *miR-92* is evolutionary conserved in Deuterostome (including vertebrates and chordates), Ecdysozoa (including flies and worms), and Lophotrochozoa, yet the remaining *mir-17-92* components are only found in vertebrates ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The functional antagonism between the more ancient *miR-92* and the newly evolved *mir-19* might result from the convergence of these two separate evolutionary paths at the origin of vertebrates. This antagonism could evolve to regulate cell proliferation and cell death downstream or independent of c-Myc in both normal development and disease. Thus, our studies suggest a novel mechanism by which a crosstalk between oncogene and tumor suppressor pathways has been hardwired through evolution into the unique gene structure of a polycistronic oncomir.

Materials and methods {#s4}
=====================

Molecular cloning {#s4-1}
-----------------

*mir-17-92 Δ92* and *mir-17-92* were amplified by PCR and subsequently cloned into the XhoI and EcoRI sites of the MSCV retrovirus vectors. In these vectors, miRNAs were placed downstream of the LTR promoter, which is followed either by a SV40-GFP cassette (for all in vivo experiments), a PGK-Puro-IRES-GFP cassette, or a SV40-CD4 cassette (for in vitro experiments) ([@bib21]). To construct MSCV*-17-92Mut92*, MSCV*-17-92Mut20*, and *MSCV-17-92Mut19b* vectors, a 12-nucleotide mutation was introduced into the seed region of the mature *miR-92*, *miR-20*, or *miR-19b* using the Quikchange XL mutagenesis kit (200521; Stratagene) and the following primers:

*Mut20* primers: GACAGCTTCTGTAGCACTAAtaaacaataatcGCAGGTAGTGTTTAGTTATC and GATAACTAAACACTACCTGCGATTATTGTTTATTAGTGCTACAGAAGCTGTC.

*Mut92* primers: CAATGCTGTGTTTCTGTATGGTtaacattaacatCCGGCCTGTTGAGTTTG and CAAACTCAACAGGCCGGATGTTAATGTTAACCATACAGAAACACAGCATTG.

*Mut19b* primers: CTGTGTGATATTCTGCTGacatttaagtacCAAAACTGACTGTGGTAGTG and CACTACCACAGTCAGTTTTGGTACTTAAATGTCAGCAGAATATCACACAG.

The loss of *miR-92, miR-20* or *miR-19b* expression and the intact expression level of the remaining *mir-17-92* components were validated using the TaqMan MicroRNA Assays (4427975; Applied Biosystems, Foster City, CA). *mir-19b-92*, *mir-19bMut92*, and *mir-19b-92Mut19b* were similarly amplified by PCR (ACTGCTCGAGAGCTTCGGCCTGTCGCCC and GTAGAATTCATGTATCTTGTAC) from the *mir-17-92*, *mir-17-92Mut92*, and *mir-17-92Mut19b* construct described above and subsequently cloned into the XhoI and EcoRI sites of the MSCV retrovirus vectors.

To construct the MSCV-Shp53 vector, shRNA against p53 was placed downstream of the LTR promoter of the MSCV-SV40-HuCD4 retroviral vector ([@bib59]). MSCV-Shfbw7 construct was kindly provided by Dr Hans Guido Wendel ([@bib35]). To construct the pRetroX-fbw7-IRES-DsRedExpress ([@bib58]), *fbw7α* ORF was placed downstream of the LTR promoter followed by an IRES-DsRed cassette.

Adoptive transfer of *Eμ-myc* HSPCs for lymphomagenesis {#s4-2}
-------------------------------------------------------

The hematopoietic stem and progenitor cells (HSPCs) were isolated from E13.5-E15.5 *Eμ-myc/+* mouse embryos and were transduced with MSCV alone or MSCV vectors expressing various *mir-17-92* derivatives. The MSCV retroviral vector used in our adoptive transfer model contains a SV40-GFP cassette that allows us to monitor transduced HSPCs both in vitro and in vivo. Infected HSPCs were subsequently transplanted into an 8- to 10-week-old, lethally irradiated C57BL/6 recipient mice. Tumor onset was subsequently monitored by weekly palpation, and tumor samples were either collected into formalin for histopathological studies, or prepared as single cell suspension for FACS analysis and for cell culture studies. Both the *Eμ-myc/+* mice and the recipient mice are on C57BL/6 background.

LT2-MYC mouse liver tumor model {#s4-3}
-------------------------------

The LT2-MYC mouse model for human hepatocellular carcinoma (HCC) is a double transgenic mouse model, in which the tetracycline transactivator protein (tTA) is driven by the hepatocyte-specific promoter, the liver activator protein (LAP) promoter, while the human c-MYC gene is driven by the tetracycline response element (TRE). The LT2-MYC model exhibits 'dox-off' regulation, where c-Myc expression is turned on in hepatocytes in the absence of doxycycline.

LT2-MYC mice taken off doxycycline-containing food, between 3--5 weeks of age, develop distinct tumor nodules around 8--12 weeks on an average ([@bib25]; [@bib48]). Total RNA was extracted from liver tumor samples from three independent mice, as well as normal livers from the doxycycline treated LT2 mice. Total RNAs were prepared using Trizol (15596018; Invitrogen) and subjected to real time PCR analyses as described below.

Cell culture and retroviral infection {#s4-4}
-------------------------------------

Primary murine B-cells were prepared from bone marrows of 4- to 6-week-old mice and were cultured in RPMI with 10% fetal bovine serum (FBS), 50 μM beta-mercaptoethanol (M3148; Sigma) and 2 ng/ml Il-7 (407-ML-005; R&D). *R26*^*MER/MER*^ and *R26*^*MER/+*^ MEFs were kindly provided by Gerald Evan's laboratory. MEFs were cultured in DMEM with 10% fetal bovine serum. *Eμ-myc* tumor cells were derived from lymphomas from the terminal-stage *Eμ-myc* animals. *Eμ-myc* lymphoma cells overexpressing various *mir-17-92* derivatives were cultured in 45% DMEM, 45% IMDM with 10% fetal bovine serum, and 50 μM β-mercaptoethanol (M3148; Sigma) on irradiated NIH-3T3 feeder cells. Immortalized human B-cell lines were cultured in RPMI with 10% FBS and 90 μM beta-mercaptoethanol. *Dicer*-deficient Hct116 cells, kindly provided by Dr Bert Vogelstein ([@bib8]), and *Fbxw7*-deficient Hct116 cells ([@bib15]) were cultured in McCoy's 5A media with 10% fetal bovine serum. Human Burkitt's lymphoma cell lines, including BL41, BL2, MutuI, Daudi, Raji (provided by Dr Terry Rabbitts), Manca, and Jiyoje were cultured in RPMI with 10% FBS.

Mouse primary B-cell cultures or MEFs were infected by MSCV retroviruses expressing various *mir-17-92* derived miRNA clusters, shRNA against p53 ([@bib59]), shRNA against fbw7 ([@bib35]), or fbw7 cDNA (pRetroX-fbw7-IRES-DsRedExpress). In [Figure 4E,F](#fig4){ref-type="fig"}, double infection was performed to obtain *R26*^*MER/MER*^ MEFs that co-expressed shRNA *p53* and *miR-92*. In this experiment, MEFs were initially infected with an ecotropic MSCV-*p53shRNA-SV40huCD4* retrovirus to a nearly 100% infection efficiency, as validated by FACS analysis using huCD4 antibody. The second infection was achieved using an amphotropic MSCV*-miR-92-PGK-Puro-IRES-GFP* retrovirus. Doubly infected cells were then selected using puromycin. In [Figure 5H](#fig5){ref-type="fig"}, double infection of *R26*^*MER/MER*^ MEFs with pRetroX-*fbw7*-IRES-DsRedExpress and MSCV*-miR-92-PGK-Puro-IRES-GFP* were similarly performed. For all experiments with primary murine B-cells, bone marrow cells were cultured for 48 hr before retroviral infection and collected or analyzed 72 hr after infection. After 5 days in culture, the percentage of B220-positive cell is 100%. In [Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, B-cells were infected with MSCV retrovirus containing a PGK-Puro-IRES-GFP cassette. FACS analysis was performed after gating on the GFP-positive population. In [Figure 5A](#fig5){ref-type="fig"}, the collected B-cells were infected with retrovirus containing SV40-CD4 cassette. Infected cells were purified with Human CD4 Micro-beads (130-045-101; Miltenyi Biotec) using MACS Purification Columns MS (130-042-201; Miltenyi Biotec).

The collection of normal and malignant B-cells in vivo {#s4-5}
------------------------------------------------------

Normal mouse B-cells were isolated from the spleen or the bone marrow of 4- to 6-week-old C57B/6J mice, using CD19 Micro-Beads (Miltenyi Biotec) or by negative selection (Easysep 19754; STEMCELL). Similarly, premalignant *Eμ-myc* B-cells were extracted from the bone marrow of 5- to 6-week-old *Eμ-myc* transgenic mice. Malignant *Eμ-myc* B-cells were extracted from the lymph node tumors of terminal-stage *Eμ-myc* mice. In addition, the normal human B-cells from peripheral blood were FACS sorted from the peripheral blood of healthy donors.

Histopathology and immunotyping {#s4-6}
-------------------------------

Mouse tissue samples were fixed in formalin (SF100-4; Fisher), embedded in paraffin (AC41677-0020; Fisher), sectioned into 5 µm tissue samples, and stained with hematoxylin and eosin (7211 & 7111, Fisher). For caspase-3 (AF835, 1:200; R&D Systems), PCNA (MS-106P, 1:200; Lab Vision Corp.), and B220 (14-0452-85, 1:100; eBioscience) detection, representative sections were deparaffinized and rehydrated in graded alcohols before subjected to antigen retrieval treatment with 10 mM sodium citrate buffer 10 min in a pressure cooker. Detection of antibody staining was carried out following standard procedures from the avidin-biotin immunoperoxidase methods. Diaminobenzidine (002014, Invitrogen) was used as the chromogen and hematoxylin as the nuclear counter stain. Quantitation of apoptosis was evaluated by counting the number of starry sky foci in three fields (40X) from seven representative animals of each genotype, as well as by counting the number of caspase-3 positive cells in three fields (40X) from five representative animals of each genotype.

To determine the cell surface markers of the lymphoma cells harvested from the animals, cells were resuspended in 10% FBS/PBS to reach a concentration of 10^7^ cells/ml. 20 μl of this cell suspension was stained with antibodies diluted in 10% FBS/PBS for 1 hr. Subsequently, cells were washed with 2% FBS/PBS and resuspended in 10% FBS/PBS for flow cytometry analysis. Antibodies used for FACS analyses include PE anti-mouse IgM (12-5790, 1:200; eBioscience), APC-Cy7 anti-mouse B220 (552094, 1:200; BD Pharmingen), APC-Cy7 anti-mouse CD4 (552051, BD Pharmingen, 1:200), PE anti-mouse CD8 (553032, 1:200; BD Pharmingen), PE anti-mouse CD25 (553866, 1:200; BD Pharmingen), and APC anti-mouse CD19 (115511, 1:100; Biolegend).

Apoptosis assays and proliferation assays {#s4-7}
-----------------------------------------

Subconfluent MSCV- or *miR-92-*infected *R26*^*MER/MER*^ MEFs were induced and serum starved by incubating the cells with 100 nM of 4-hydroxytamoxifen (H6278; Sigma) in DMEM with 0.2% fetal bovine serum for 12--24 hr before harvesting the cells for apoptosis analyses using APC-Annexin V antibody (550475, 1:50; BD Pharmingen) and 7AAD staining solution (559925; BD Pharmingen). To evaluate the apoptotic effects of *miR-92* in our adoptive transfer model in vivo, we collected premalignant *Eμ-myc* B-cells from spleen or bone marrow of well-controlled *Eμ-myc/92* and *Eμ-myc/MSCV* mice at 5 weeks after adoptive transfer and measured the extent of apoptosis by FACS. Apoptosis in GFP-positive B220-positive premalignant B-cells was measured using the Caspase Detection Kit (Calbiochem, Red-VAD-FMK) following the manufacturer's instructions. To quantitate cell proliferation, 10 μM of BrdU was used to label primary B-cells for 4 hr and MEFs for 30 min. The percentage of BrdU-positive cells was determined using the Flow BrdU kit (552598; BD Pharmingen).

Real time PCR and western analyses {#s4-8}
----------------------------------

TaqMan MicroRNA Assays (Applied Biosystems) were used to measure the level of mature miRNAs, including *miR-17, 18, 19a, 20, 19b*, and *92* (4427975; ABI). mRNA level for *perp* (GACCCCAGATGCTTGTTTTC, GGGTTATCGTGAAGCCTGAA), *noxa* (GGAGTGCACCGGACATAACT, TGAGCACACTCGTCCTTCAA), *puma* (GCGGCGGAGACAAGAAGA, AGTCCCATGAAGAGATTGTAC), p21 (ACGGTGGAACTTTGACTTCG, CAGGGCAGAGGAAGTACTGG), *bax* (GTTTCATCCAGGATCGAGCAG, CCCCAGTTGAAGTTGCCATC), *mdm2* (CTCTGGACTCGGAAGATTACAGCC, CCTGTCTGATAGACTGTCACCCG), *p53* (AACCGCCGACCTATCCTTAC, TCTTCTGTACGGCGGTCTCT), *ccnb1* (AAGGTGCCTGTGTGTGAACC, GTCAGCCCCATCATCTGCG), *ccnb2* (GCCAAGAGCCATGTGACTATC, CAGAGCTGGTACTTTGGTGTTC), *cdc20* (AGACCACCCCTAGCAAACCT, GACCAGGCTTTCTGATGCTC), *cdc25b* (ATTCTCGTCTGAGCGTGGAC, GCTGTGGGAAGAACTCCTTG), *fbw7* (CGGCTCAGACTTGTCGATACT, CTTGATGTGCAACGGTTCAT), *gtse1* (GCTTTGCCTGTGAGAGGAAG, CACTCTGGGATCCCTTTTCA), *bid* (CTGCCTGTGCAAGCTTACTG, GTCTGGCAATGTTGTGGATG), *pten* (CACAATTCCCAGTCAGAGGCG, GCTGGCAGACCACAAACTGAG), *bim* (ACCACTATCTCAGTGCAATGGCTTCC, CGGTAATCATTTGCAAACACCCTCCTTG), *cdk4* (TGGTACCGAGCTCCTGAAGT, GTCGGCTTCAGAGTTTCCAC), *c-myc* (GTGCTGCATGAGGAGACACCGCC, GCCCGACTCCGACCTCTTGGC), *Pirh2* (TGCAGTGCATCAACTGTGAA, CAAACAGGTGGCAAATACTGC), *Ppp2r5d* (CCGTGATGTTGTCACTGAGG, ACTCTGCTCCTGTGGGATTC), *Dyrk2* (CCAGCAACGCTACCACTACA, AACAGCTGCTGAACCTGGAT), *Romo1* (ATTCGGAGTGAGACGTCGAG, TGACGAAGCCCATCTTCAC), *Pak2* (TTGGCTTTGATGCTGTTACG, CACTGCCTGAGGGTTCTTCT), *Trpc4ap* (CGCAAATGTCCTTCCTCTTC, GCCAGCATCAGGATTACCAG), and *Axin1* (AGGACGCTGAGAAGAACCAG, CTGCTTCCTCAACCCAGAAG) were determined using real time PCR analyses with SYBR (KK4605; Kapa Biosystems). *Actin* (GATCTGGCACCACACCTTCT, GGGGTGTTGAAGGTCTCAAA) was used as a normalization control in all our real time PCR analysis with SYBR. U6 snRNA assay (4427975; ABI) was used as a normalization control in all our TaqMan MicroRNA Assays (Applied Biosystems).

For western analyses, all samples were directly collected into Laemmli buffer. p53 (1C12; Cell Signaling), Arf (5-C3-1; Novus), and c-Myc (1472-1; Epitomics) antibodies were used at 1:1000 dilution. FLAG (M2; Sigma) and Tubulin (12G10) were used at 1:2500 dilution. HRP conjugated secondary antibodies (Santa Cruz Biotechnology, sc-2004 sc-2005 and sc-2006) were used at 1:5000.

Microarray analyses {#s4-9}
-------------------

Three independent *R26*^*MER/MER*^ MEF lines were infected by MSCV vector alone or by MSCV vector encoding *miR-92*. These MEFs were induced and serum starved by incubating the cells with 100 nM of 4-hydroxytamoxifen (H6278; Sigma) in DMEM with 0.2% fetal bovine serum for 12 hr before harvesting the cells for RNA preparation. Total RNAs were prepared using Trizol (15596018; Invitrogen), and subjected to microarray analysis using Affymetrix chip Mouse 430_2. To identify differentially expressed genes that could be regulated by *miR-92*, we used gcRMA in the bioconductor package ([@bib57]) and SAM (Significance Analysis of Microarrays) ([@bib52]) for statistical analysis of our microarray data. Gene expression signals were estimated from the probe signal values in the CEL files using statistical algorithm gcRMA. This data processing at the probe level includes background signal subtraction and quantile normalization to facilitate the comparison among microarrays. SAM was then used to identify the genes with significant expression level alterations between *miR-92* overexpressing MEFs and the control MEFs. The genes with at least 1.5-fold expression level change and FDR \<1% were regarded as differentially expressed genes. Pathway analyses were performed on upregulated and downregulated genes using the KEGG database ([@bib9]).

*Xenopus* embryo apoptosis assays {#s4-10}
---------------------------------

*Xenopus laevis* eggs were collected, fertilized, and embryos cultured by standard procedures. The *miR-19b* mimics were produced from the annealing products of 5′UGUGCAAAUCCAUGCAAAACUGA3′ and 5′AGUUUUGCAGGUUUGCAUCCAUU3′ (IDT).

The *miR-17* mimics were produced from the annealing products of 5′CAAAGUGCUUACAGUGCAGGUAGU3′ and 5′UACUGCAGUGAAGGCACUUGUAG3′(IDT).

The *miR-18* mimics were produced from the annealing products of 5′UAAGGUGCAUCUAGUGCAGAUAG3′ and 5′ACUGCCCUAAGUGCUCCUUCUG3′(IDT).

The *miR-19a* mimics were produced from the annealing products of 5′AGUUUUGCAUAGUUGCACUA3′ and 5′UGUGCAAAUCUAUGCAAAACUGA3′(IDT).

The *miR-20* mimics were produced from the annealing products of 5′UAAAGUGCUUAUAGUGCAGGUAG3′ and 5′ACUGCAUAAUGAGCACUUAAAGU3′(IDT).

The *miR-92* mimics were produced from the annealing products of 5′UAUUGCACUUGUCCCGGCCUG3′ and 5′AGGUUGGGAUUUGUCGCAAUGCU3′(IDT).

The annealing of miRNA mimics were performed by combining two complimentary RNA oligos at a stock concentration of 1 μg/μl, heating the oligos to 80°C for 1 min, and then cooling down to room temperature to allow duplexes to form. The same was done for generating the mutated *miR-19* mimics (*Mut-miR-19*), by annealing 5′UCAGGUAAUCCAUGCAAAACUGA3′ and 5′AGUUUUGCAGGUUACCUUCGAUU3′, and mutated *miR-92* mimics (*Mut-miR-92*) by annealing 5′UUAUCGACUUGUCCCGG3′ and 5′GGUUGGGAUUGGUUCGA 3′.

*Xenopus* embryos were injected into both cells at the two-cell stage with 2 ng of each RNA ([@bib54]). The pcDNA3-*myc-AGO2* vector, kindly provided by Dr Greg Hannon, was cut using ScaI; and the synthetic *hAGO2* mRNAs were transcribed using mMessage mMachine T7 kit (Ambion). When indicated, a total of 0.5 ng *hAGO2* mRNA ([@bib29]) was injected into two-cell stage embryos either alone or with 2 ng of each miRNA ([@bib32]). The embryos were then treated with hydroxyurea (H8627; Sigma) at a final concentration of 5 mM from stage 3 until stage 10. Apoptotic embryos were scored as those containing any apoptotic cells based on morphological changes.

Luciferase assays {#s4-11}
-----------------

A luciferase reporter fused with the *fbw7* 3′UTR was kindly provided by Dr Hans-Guido Wendel ([@bib35]). In this psiCHECK-2 based reporter, the *fbw7* 3′UTR was cloned downstream of the *Renilla* luciferase reporter, and a separate *firefly* luciferase cassette was used as a transfection control. Because the two predicted *miR-92* binding sites are close to each end of the 3′UTR, we mutated the *miR-92* binding sites by PCR using the following primers:

3′UTR-Fbw7-Mut-Xho1-F (GATCTCGAGCAAGACGACTCTCTAAATCCAACTATTCTTT) and 3′UTR-Fbw7-mut-Not1-R (ATGCGGCCGCAACACATTTAGTTATAAGAAAATAAAATTT). The PCR fragment was subsequently cloned into the XhoI and Not1 sites of the psiCHECK-2 vector. The reporter construct, together with 50 nM *miR-92* mimics, was transfected into *Dicer*-deficient Hct116 cells ([@bib8]), with transfection of *miR-17* or *miR-18* as negative controls. Luciferase activity of each construct was determined by dual luciferase assay (E19100; Promega) 48 hr post-transfection following the manufacturer's instructions. The *miR-17* mimics were produced by annealing 5′CAAAGUGCUUACAGUGCAGGUAGU3′ and 5′UACUGCAGUGAAGGCACUUGUAG3′. The *miR-18* mimics were produced by annealing 5′UAAGGUGCAUCUAGUGCAGAUAG3′ and 5′ACUGCCCUAAGUGCUCCUUCUG3′.

The *miR-92* mimics were produced by annealing 5′UAUUGCACUUGUCCCGGCCUG3′ and 5′AGGUUGGGAUUUGUCGCAAUGCU3′.

Fbw7α immunoprecipitation and western analyses {#s4-12}
----------------------------------------------

Because Fbxw7-substrate degradation was regulated in a cell-cycle-dependent manner, we used serum starvation synchronized MEFs to study Fbw7 regulation by *miR-92* during cell cycle progression. MEFs were made quiescent by serum starvation; then Fbw7 expression was examined following release into serum. Cells were lysed in NP-40 buffer supplemented with protease inhibitors. Lysates were normalized and immunoprecipitated with polyclonal anti-Fbw7 antibody kindly provided by Dr Bruce Clurman ([@bib14]), followed by immunoblotting with polyclonal anti-Fbw7 antibody (A301-720A; Bethyl Laboratories). Wild-type and *FBW7*^*−/−*^ Hct116 cells were used, respectively, as positive and negative controls.

The construction of the pFLAG-Fbw7α-3′UTR plasmid was previously described ([@bib58]). The construct was transfected into the *Dicer*-deficient Hct116 cells together with 50 nM of *miR-92* mimics or siRNA against GFP as indicated. Anti-FLAG (M2; Sigma) antibody was used to detect the FLAG-Fbw7α by western blot 48 hr after transfection.

Cyclin E-dependent kinase assays {#s4-13}
--------------------------------

Cyclin E-CDK complexes were immunoprecipitated from MSCV or *miR-92* infected *Rosa26*^*MER/MER*^ MEFs extracts using affinity-purified polyclonal antibody, provided by Dr Bruce Clurman ([@bib38]). Cyclin E immunoprecipitates were then incubated with purified histone subunit H1 (Sigma) and (gamma-^32^P)ATP to measure cyclin E-dependent kinase activity. The anti-Grb2 monoclonal (BD Biosciences) antibody was used a normalization control.
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Thank you for sending your work entitled "A component of the *mir-17-92* polycistronic oncomir promotes oncogene-dependent apoptosis" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, one of whom, Chi Van Dang, is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The manuscript by Olive et al. describes a very intriguing finding: while as a whole the *miR-17∼92* cluster accelerates Myc-driven lymphomagenesis, its *miR-92* component acts as a built-in damper, which induces apoptosis. Furthermore, deleting this component results in earlier-onset lymphomas. This central discovery was made using a model developed by Dr. He and her collaborators (Nature 2005; G&D 2009), wherein premalignant hematopoietic progenitors from *Eμ-myc* mice are transduced with various miR-encoding retroviruses and used to reconstitute irradiated recipients. The key data presented in [Figures 1--3](#fig1 fig2 fig3){ref-type="fig"} are generally crisp, compelling, and easy to interpret. However several issues remain to be resolved.

*Specificity of* miR-92 *activity:*

1\) The authors documented that *miR-92* targets Fbw7 and thereby enhances MYC protein levels. While [Figure 5D](#fig5){ref-type="fig"} shows that *miR-92* can repress a Fbw7 3\'UTR luciferase reporter construct or Fbw7 cDNA expression construct, specificity of *miR-92* should be established via mutating the predicted *miR-92* binding site(s) within the 3\'UTR and determine whether they are required for this repression.

2\) Further experiments are needed to show whether the *miR-92*-Fbw7-Myc axis is fully responsible for *miR-92*\'s pro-apoptotic effects. In [Figure 5F](#fig5){ref-type="fig"}, it is shown that Fbw7 shRNA partially recapitulates the effect of *miR-92* expression on Myc-mediated apoptosis in MEFs. The levels of Myc protein should be shown in this experiment. If Fbw7 knockdown fully recapitulates the *miR-92*-induced Myc levels yet does not fully recapitulate the degree of *miR-92*-induced apoptosis, it suggests that *miR-92* engages additional mechanisms to induce apoptosis. To further investigate this issue, the authors should express ectopic Fbw7 (which does not have the miR seed sequence) at physiologic levels and see if this rescues the apoptotic phenotype of *miR-92*. These experiments should establish whether upregulation of Myc by *miR-92* is the entire story or whether additional pro-apoptotic mechanisms exist. The authors are not required to identify such additional mechanisms in the current paper but it is important to know whether they exist.

3\) To further substantiate their model, the authors should measure Fbw7 and Myc protein levels in *Eμ-myc* lymphoma cells expressing wild-type *miR-17-92* versus those expressing *miR-17-92Δ92*. If *miR-92*-mediated Fbw7 repression/Myc induction cannot be demonstrated in this setting, the proposed mechanism, while elegant, could be completely irrelevant.

4\) Along the same lines, what is the evidence that the effects of *miR-92* on Myc levels are Fbw7-mediated? Perhaps Fbw7-null HCT116 cells could be used to establish causality.

5\) The authors make a claim that that *miR-92* is processed less efficiently in murine and human lymphomas than *miR-19*, the main oncogenic component of the cluster. This is an important claim, however, some of the quantifications are difficult to understand. For example, in panel 7D, *miR-19* and *-92* levels in Burkitt\'s cell lines are normalized separately for those found in "normal PB-cells". Assuming that PB stands for "peripheral blood", this does not appear to be a relevant control, since a circulating lymphocyte is not a cell of origin for Burkitt\'s -- or other human lymphomas, for that matter. A direct comparison between *miR-19* and *miR-92* levels would be more helpful. According to a recent profiling paper \[[doi:10.1038/bcj.2012.1](http://dx.doi.org/10.1038/bcj.2012.1)\], *miR-19b* and *miR-92* are overexpressed at comparable levels in Burkitt\'s samples.

*Conceptual framework*:

1\) Although the authors focused on this 'oncoMir' cluster and studied its oncogenic properties, it would be terrific for the authors to discuss the potential physiological importance of this cluster with regard to its evolution as presented in the manuscript. In particular, it would be safe to assume that this cluster evolved to regulate cell growth and proliferation downstream or independent of MYC. Hence, the different miRs in the cluster might be subject to regulation via microRNA processing in addition to the expression of the cluster mRNA precursor. In this regard, are the relative levels of *miR-92* to other miRs in the cluster differentially affected by cellular stresses that lead to apoptosis (serum or growth factor deprivation, nutrient deprivation?)? Some discussion on this aspect of *miR-17-92* function could be very useful for the field.

2\) In the Discussion, the authors describe *miR-92* as conferring negative feedback on the oncogenic activity of *miR-17-92*. Given that *miR-17-92* is transcriptionally activated by Myc and Myc dosage is positively regulated by *miR-92*, a positive feedback loop is also established. This concept should be discussed.

*Influence of* miR-92 *on the miR cluster*:

1\) The expression of the miRNAs derived from the various MSCV constructs (*miR-17-92*; *miR-17-92Δ92*; *miR-17-92Mut92*) is tested by transducing 3T3 cells with these retroviruses ([Figure 1B](#fig1){ref-type="fig"}). However, the conclusions of the paper rest heavily upon the assumption that mutating *miR-92* does not affect the expression of other miRNAs in the cluster in B cells (where the oncogenic activity is examined most extensively). Therefore it is important to examine the miRNA levels in *Eμ-Myc* lymphoma cells or primary B cells infected with the various viruses to confirm their findings in 3T3 cells.

10.7554/eLife.00822.017

Author response

*Specificity of* miR-92 *activity*:

*1) The authors documented that* miR-92 *targets Fbw7 and thereby enhances MYC protein levels. While* [*Figure 5D*](#fig5){ref-type="fig"} *shows that* miR-92 *can repress a Fbw7 3\'UTR luciferase reporter construct or Fbw7 cDNA expression construct, specificity of* miR-92 *should be established via mutating the predicted* miR-92 *binding site(s) within the 3\'UTR and determine whether they are required for this repression*.

We thank the reviewers for this comment. We have constructed luciferase reporters that carry either a wild type *fbw7* 3'UTR, or a mutated *fbw7* 3'UTR with defective *miR-92* binding sites. Using these reporters, we clearly demonstrated that *miR-92* overexpression could downregulate the expression of the luciferase reporter carrying the wild type *fbw7* 3'UTR, but not the luciferase reporter with the mutated *fbw7* 3'UTR. This result, shown in [Figure 5D](#fig5){ref-type="fig"}, demonstrates that Fbw7 is specifically repressed by *miR-92*, and that the *miR-92* binding is required for its repression on Fbw7.

*2) Further experiments are needed to show whether the* miR-92*-Fbw7-Myc axis is fully responsible for* miR-92*\'s pro-apoptotic effects. In* [*Figure 5F*](#fig5){ref-type="fig"}*, it is shown that Fbw7 shRNA partially recapitulates the effect of* miR-92 *expression on Myc-mediated apoptosis in MEFs. The levels of Myc protein should be shown in this experiment. If Fbw7 knockdown fully recapitulates the* miR-92*-induced Myc levels yet does not fully recapitulate the degree of* miR-92*-induced apoptosis, it suggests that* miR-92 *engages additional mechanisms to induce apoptosis. To further investigate this issue, the authors should express ectopic Fbw7 (which does not have the miR seed sequence) at physiologic levels and see if this rescues the apoptotic phenotype of* miR-92*. These experiments should establish whether upregulation of Myc by* miR-92 *is the entire story or whether additional pro-apoptotic mechanisms exist. The authors are not required to identify such additional mechanisms in the current paper but it is important to know whether they exist*.

To investigate if the *miR-92*-Fbw7-Myc axis is fully responsible for *miR-92*\'s pro-apoptotic effects in vitro, we compared the effect of *miR-92* overexpression and *fbw7* knockdown on c-Myc protein level in *R26*^*MER/MER*^ mouse embryonic fibroblasts (MEFs) ([Figure 5--figure supplement 1F](#fig5s1){ref-type="fig"}). In this experiment, *fbw7* knockdown largely recapitulated the extent of c-Myc upregulation by *miR-92*. This is consistent with our observation that the repression of *fbw7* by *miR-92* is essential for *miR-92* to upregulate c-Myc ([Figure 5--figure supplement 1E](#fig5s1){ref-type="fig"}, also see our response to \#4). Since *fbw7* knockdown only partially phenocopies *miR-92* in promoting c-Myc induced apoptosis, one possible scenario is that *miR-92* engages additional mechanisms to promote c-Myc apoptosis. Nevertheless, the *miR-92*-Fbw7-Myc axis does constitute a major mechanism to mediate the pro-apoptotic effects of *miR-92*. To examine the importance of *fbw7* in mediating the apoptotic effects by *miR-92*, we expressed *fbw7* in *R26*^*MER/MER*^ mouse embryonic fibroblasts (MEFs) with and without *miR-92* overexpression. In this experiment, the *fbw7* cDNA introduced did not contain its 3'UTR, thus was not regulated by *miR-92*. Although *miR-92* overexpression in *R26*^*MER/MER*^ MEFs invariably enhanced c-Myc induced apoptotic response upon MycERT([@bib3]) activation, expression of *fbw7* abolished this apoptotic effect of *miR-92* ([Figure 5H](#fig5){ref-type="fig"}). Thus, the ability of *miR-92* to increase c-Myc protein level through *fbw7* repression constitutes the major mechanism underlying its pro-apoptotic effects.

*3) To further substantiate their model, the authors should measure Fbw7 and Myc protein levels in* Eμ-myc *lymphoma cells expressing wild-type* miR-17-92 *versus those expressing* miR-17-92Δ92*. If* miR-92*-mediated Fbw7 repression/Myc induction cannot be demonstrated in this setting, the proposed mechanism, while elegant, could be completely irrelevant*.

We thank the reviewers for this insightful comment. The experiment proposed here, if performed successfully, would strongly support our hypothesis. However, we have encountered technical limitations in detecting the endogenous Fbw7 protein in our tumor lysates. In our experience, we have not found any Fbw7 antibodies that can reliably detect endogenous Fbw7 proteins by simple immunoblotting. We have tested several commercial antibodies for detection of endogenous Fbw7, including those sold by Abcam, Sigma, and Invitrogen, and we are unable to detect endogenous Fbw7 cleanly, using proper controls (Fbw7-null HCT116 cell lysate). In lysates from cultured MEFs, which we can expand greatly, we use an immunoprecipitation-western blot method that does detect endogenous Fbw7 ([Figures 5E](#fig5){ref-type="fig"}), as detailed in our Methods section. The limitation of this approach is that one needs a large amount of cell pellet for this experiment. As an alternative, we performed *fbw7* QPCR analyses, using *Eμ-myc/17-92*, *Eμ-myc/17-19b*, and *Eμ-myc/MSCV* lymphoma cells. Consistent with our hypothesis, Eμ-myc/17-92 B-lymphoma cells exhibited significantly decreased levels of *fbw7* mRNA, when compared to those in *Eμ-myc/17-19b* or *Eμ-myc/MSCV* lymphoma cells ([Figure 5--figuresupplement 1F](#fig5s1){ref-type="fig"}).

We also measured c-Myc protein levels in several lines of *Eμ-myc/17-92*, *Eμ-myc/17-19b*, and *Eμ-myc/MSCV* lymphoma cells, to determine if there is a correlation between *miR-92* overexpression and increased c-Myc dosage. However, we observed no differences in the c-Myc protein levels among these terminal tumor cells (data not shown). Previous studies have demonstrated that the terminal *E-myc* tumors, which are defective for c-Myc-induced apoptosis, clearly favor a high dosage of c-Myc to promote and maintain oncogenesis. In addition to the *miR-92*-Fbw7 axis that regulates c-Myc dosage, a *miR-92* and*fbw7* independent mechanism can also enhance c-Myc dosage in the transformed *Eμ-myc* lymphoma cells. Thus, comparing the c-Myc level in the terminal *Eμ-myc/17-92*, *Eμ-myc/17-19b*, and *Eμ-myc/MSCV* lymphoma cells is unlikely to reveal the importance of c-Myc regulation by the *miR-92*-Fbw7 axis, because this regulation plays an essential role in the early stages of lymphoma development ([Figure 3A, 3B](#fig3){ref-type="fig"}, [Figure 6B](#fig6){ref-type="fig"}).

*4) Along the same lines, what is the evidence that the effects of* miR-92 *on Myc levels are Fbw7-mediated? Perhaps Fbw7-null HCT116 cells could be used to establish causality*.

In the revised manuscript, we have clearly demonstrated that the overexpression of *miR-92* increases c-MYC protein levels in a *FBW7*-dependent manner. The effect of *miR-92*to upregulate c-MYC protein level was observed in wild type Hct116 cells, but was largely absent in *FBW7*^-/-^ Hct116 cells ([Figure 5--figure supplement 1E](#fig5s1){ref-type="fig"}). These results argue that the repression of *FBW7* by *miR-92* is essential for *miR-92* to upregulate the protein level of c-MYC.

*5) The authors make a claim that that* miR-92 *is processed less efficiently in murine and human lymphomas than* miR-19*, the main oncogenic component of the cluster. This is an important claim, however, some of the quantifications are difficult to understand. For example, in panel 7D,* miR-19 *and* -92 *levels in Burkitt\'s cell lines are normalized separately for those found in "normal PB-cells". Assuming that PB stands for "peripheral blood", this does not appear to be a relevant control, since a circulating lymphocyte is not a cell of origin for Burkitt\'s -- or other human lymphomas, for that matter. A direct comparison between* miR-19 *and* miR-92 *levels would be more helpful. According to a recent profiling paper \[*[*doi:10.1038/bcj.2012.1*](http://dx.doi.org/10.1038/bcj.2012.1)*\],* miR-19b *and* miR-92 *are overexpressed at comparable levels in Burkitt\'s samples*.

We thank the reviewers for the constructive comments. We have realized that our wording in the previous manuscript has caused confusion. What is clear from our studies is that the ratio of *miR-19* to *miR-92* is greater in B-lymphomas than in normal B-cells. In other words, when normalized to the respective miRNA levels in normal B-cells, mature *miR-19* exhibited a greater increase in premalignant and malignant *Eμ-myc* B-cells than mature *miR-92* ([Figure 7A, 7B, 7C](#fig7){ref-type="fig"}). Since *miR-19*and *miR-92* are coregulated transcriptionally, we speculate, but do not claim, that a differential miRNA biogenesis and/or turn over could explain the differential increase of these two miRNAs. Given their functional antagonism, the ratio between *miR-19* and *miR-92* is the key determinate for the oncogenic activity of *mir-17-92* in the context of the *Eμ-myc* B-lymphoma model. What we showed here strongly supported an altered *miR-19*:*miR-92* ratio in premalignant and malignant *Eμ-myc* B-cells, which favored a greater *miR-19* increase to drive oncogenesis.

Per the reviewers' request, we directly compared the *miR-19* and *miR-92* levels using miRNA Taqman asssays. Our data suggest a ∼2-5 fold increase in the absolute level of *miR-19b* than *miR-92* in transformed B-cells, both in mouse and in human (data not shown). However, we must point out the intrinsic caveats associated with absolute quantitation of different mature miRNAs. Currently, two methods are most popular for the absolute quantitation of mature miRNAs miRNA Taqman assays or high-throughput sequencing (HTS). However, both methods have technical caveats that prevent an accurate quantitation. For the Taqman miRNA assays, the different RT efficiency for different mature miRNAs can introduce systematic bias in quantitation and preclude an accurate quantitation of different mature miRNAs. For the HTS approach, different mature miRNAs have different cloning efficiency due to RNA-ligase-dependent bias (Hafner et al., RNA 2011). Given the intrinsic technical limitations to accurately compare copy numbers of different mature miRNAs, we think it is the most appropriate to leave this out for our manuscript. We included a discussion about this issue in the revised manuscript.

We also clarified the legend of our [Figure 7](#fig7){ref-type="fig"} to indicate the use of normal B-cells from periphery blood as a control for our Burkitt's lymphoma cell lines. We admit that using B-cells from peripheral blood to control for human Burkitt's lymphoma cell lines is less than ideal. However, such comparison has been used routinely for many published studies due to the difficulty to acquire human GC B-cell RNA as a proper control. We have included a statement in our revised manuscript to discuss this caveat for our comparison.

Conceptual framework:

*1) Although the authors focused on this 'oncoMir' cluster and studied its oncogenic properties, it would be terrific for the authors to discuss the potential physiological importance of this cluster with regard to its evolution as presented in the manuscript. In particular, it would be safe to assume that this cluster evolved to regulate cell growth and proliferation downstream or independent of MYC. Hence, the different miRs in the cluster might be subject to regulation via microRNA processing in addition to the expression of the cluster mRNA precursor. In this regard, are the relative levels of* miR-92 *to other miRs in the cluster differentially affected by cellular stresses that lead to apoptosis (serum or growth factor deprivation, nutrient deprivation?)? Some discussion on this aspect of* miR-17-92 *function could be very useful for the field*.

We thank the reviewers for the constructive comment. We have included a brief discussion on the functional significance of the *mir-17-92* polycistronic structure in its physiological functions.

*2) In the Discussion, the authors describe* miR-92 *as conferring negative feedback on the oncogenic activity of* miR-17-92*. Given that* miR-17-92 *is transcriptionally activated by Myc and Myc dosage is positively regulated by* miR-92*, a positive feedback loop is also established. This concept should be discussed*.

We thank the reviewers for the insightful comment. In the revised manuscript, we have included a discussion on the positive feedback loop between *mir-17-92* and c-Myc.

Influence of *miR-92* on the miR cluster:

*1) The expression of the miRNAs derived from the various MSCV constructs (*miR-17-92*;* miR-17-92Δ92*;* miR-17-92Mut92*) is tested by transducing 3T3 cells with these retroviruses (*[*Figure 1B*](#fig1){ref-type="fig"}*). However, the conclusions of the paper rest heavily upon the assumption that mutating* miR-92 *does not affect the expression of other miRNAs in the cluster in B cells (where the oncogenic activity is examined most extensively). Therefore it is important to examine the miRNA levels in* Eμ-Myc *lymphoma cells or primary B cells infected with the various viruses to confirm their findings in 3T3 cells*.

We have examined the expression of all *mir-17-92* components in the *Eμ-myc* B-lymphoma cells that overexpress *mir-17-92*, *mir-17-92Δ92*, or *mir-17-92Mut92*. Consistent with our results in the 3T3 cells ([Figure 1--figure supplement 1D](#fig1s1){ref-type="fig"}), mutation or deletion of *miR-92* specifically disrupted the *miR-92* expression in B-cell, without affecting the expression of the remaining *mir-17-92* components ([Figure 1D](#fig1){ref-type="fig"}).

[^1]: These authors contributed equally to this work.

[^2]: Vollum Institute, Oregon Health and Science University, Portland, United States.

[^3]: 1 out of 6 samples predominantly contains IgM+ cells, with a small percentage of IgM− cells.

[^4]: 3 out of 5 samples predominantly contain IgM+ cells, with a small percentage of IgM− cells.

[^5]: 1 out of 3 samples predominantly contains IgM+ cells, with a small percentage of IgM− cells.

[^6]: 1 out of 2 samples predominantly contains IgM+ cells, with a small percentage of IgM− cells.
